Conference Coverage

Complete Conference Coverage

Apalutamide, Enzalutamide May Improve Prostate Cancer Outcomes

Apalutamide, Enzalutamide May Improve Prostate Cancer Outcomes

In separate studies, apalutamide, an investigational agent, and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.

Cabozantinib Superior to Sunitinib for First-Line RCC Treatment Across all Subgroups

Cabozantinib Superior to Sunitinib for First-Line RCC Treatment Across all Subgroups

Findings from the phase 2 CABOSUN study showed that, compared with sunitinib, cabozantinib improves PFS and the ORR among patients with advanced RCC.

Ramucirumab Plus Docetaxel May Improve QoL in Urothelial Carcinoma

Ramucirumab Plus Docetaxel May Improve QoL in Urothelial Carcinoma

The impact of this treatment on quality of life was not previously reported.

Adjuvant Docetaxel May Worsen Outcomes vs Surveillance in Prostate Cancer

Adjuvant Docetaxel May Worsen Outcomes vs Surveillance in Prostate Cancer

It was previously unknown whether chemotherapy or surveillance leads to improved outcomes in prostate cancer post-prostatectomy.

Cabozantinib May Improve Survival in mCRPC Patient Subgroup

Cabozantinib May Improve Survival in mCRPC Patient Subgroup

COMET-1 and COMET-2 previously showed no overall survival benefit with cabozantinib.

Adjuvant Sunitinib Increases Mortality Risk Among Older Women With Renal Cell Cancer

Adjuvant Sunitinib Increases Mortality Risk Among Older Women With Renal Cell Cancer

Previous findings suggested that there were no benefits to overall survival or disease-free survival with VEGF-TKIs vs placebo.

5-FU/Cisplatin, Gemcitabine May Be Effective Options for Invasive Bladder Cancer

5-FU/Cisplatin, Gemcitabine May Be Effective Options for Invasive Bladder Cancer

This study was designed to evaluate the efficacy of each treatment using 3-year distant metastasis-free survival as a primary outcome.

Antibiotics May Indirectly Improve PFS Among Patients With RCC Receiving TKIs

Antibiotics May Indirectly Improve PFS Among Patients With RCC Receiving TKIs

Patients receiving VEGF-TKIs are likely to have treatment dose reductions, delays, or interruptions because of diarrhea, which occurs in about 50% of cases.

Papillary Renal Cell Carcinomas May Respond to Crizotinib

Papillary Renal Cell Carcinomas May Respond to Crizotinib

Patients with PRCC1 frequently show MET mutations. Crizotinib, a dual inhibitor of MET and ALK, has shown promising activity in MET-altered cancers.

Nivolumab Monotherapy May Yield 8% Complete Response Rate in Urothelial Carcinoma

Nivolumab Monotherapy May Yield 8% Complete Response Rate in Urothelial Carcinoma

Seventy-eight patients with metastatic urothelial carcinoma received intravenous nivolumab until disease progression or discontinuation.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs